Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. (“4D Molecular” or “the Company”) (NASDAQ: FDMT). Investors who purchased 4D Molecular securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/FDMT.

Investigation Details

On July 17, 2024, 4D Molecular released the interim results of its Phase 2 PRISM study on Intravitreal 4D-150. Despite the Company billing the results as positive, 4D Molecular stock dropped roughly 35% during same-day trading.

What's Next?

If you are aware of any facts relating to this investigation or purchased 4D Molecular securities, you can assist this investigation by visiting the firm’s site: https://bgandg.com/FDMT. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240729433935/en/

The 4D Molecular Therapeutics Stock at the time of publication of the news with a fall of -6,05 % to 17,24USD on Nasdaq stock exchange (29. Juli 2024, 21:50 Uhr).